Cover Image
市場調查報告書

Vical Incorporated:產品平台分析

Vical Incorporated - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224604
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Vical Incorporated:產品平台分析 Vical Incorporated - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 34 Pages
簡介

Vical Incorporated是以預防及治療威脅生命的疾病,並基於DNA遞送技術進行生物醫藥品的研究開發的生物醫藥品企業。

本報告提供Vical Incorporated的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Vical Incorporated的基本資料

  • Vical Incorporated概要
  • 主要資訊
  • 企業資料

Vical Incorporated:R&D概要

  • 主要的治療範圍

Vical Incorporated:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Vical Incorporated:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • IND/CTA 申請產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式

Vical Incorporated:藥物簡介

  • VCLHB-01
  • VCLHM-01
  • CyMVectin
  • ASP-2397
  • 麻疹疫苗

Vical Incorporated:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Vical Incorporated:最近的開發平台趨勢

Vical Incorporated:暫停中的計劃

Vical Incorporated:中止發的開發中產品

  • 中止發的開發中產品簡介
    • HIV Vaccine

Vical Incorporated:企業發表

Vical Incorporated:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07301CDB

Summary

Global Markets Direct's, 'Vical Incorporated - Product Pipeline Review - 2015', provides an overview of the Vical Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vical Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vical Incorporated including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vical Incorporated's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vical Incorporated's pipeline products

Reasons to buy

  • Evaluate Vical Incorporated's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vical Incorporated in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vical Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vical Incorporated and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vical Incorporated
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vical Incorporated and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vical Incorporated Snapshot
    • Vical Incorporated Overview
    • Key Information
    • Key Facts
  • Vical Incorporated - Research and Development Overview
    • Key Therapeutic Areas
  • Vical Incorporated - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Vical Incorporated - Pipeline Products Glance
    • Vical Incorporated - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Vical Incorporated - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Vical Incorporated - Drug Profiles
    • VCLHB-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCLHM-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CyMVectin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-2397
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles (bivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vical Incorporated - Pipeline Analysis
    • Vical Incorporated - Pipeline Products by Target
    • Vical Incorporated - Pipeline Products by Route of Administration
    • Vical Incorporated - Pipeline Products by Molecule Type
  • Vical Incorporated - Recent Pipeline Updates
  • Vical Incorporated - Dormant Projects
  • Vical Incorporated - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • HIV Vaccine
  • Vical Incorporated - Company Statement
  • Vical Incorporated - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vical Incorporated, Key Information
  • Vical Incorporated, Key Facts
  • Vical Incorporated - Pipeline by Indication, 2015
  • Vical Incorporated - Pipeline by Stage of Development, 2015
  • Vical Incorporated - Monotherapy Products in Pipeline, 2015
  • Vical Incorporated - Partnered Products in Pipeline, 2015
  • Vical Incorporated - Partnered Products/ Combination Treatment Modalities, 2015
  • Vical Incorporated - Out-Licensed Products in Pipeline, 2015
  • Vical Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Vical Incorporated - Phase I, 2015
  • Vical Incorporated - IND/CTA Filed, 2015
  • Vical Incorporated - Preclinical, 2015
  • Vical Incorporated - Pipeline by Target, 2015
  • Vical Incorporated - Pipeline by Route of Administration, 2015
  • Vical Incorporated - Pipeline by Molecule Type, 2015
  • Vical Incorporated - Recent Pipeline Updates, 2015
  • Vical Incorporated - Dormant Developmental Projects,2015
  • Vical Incorporated - Discontinued Pipeline Products, 2015

List of Figures

  • Vical Incorporated - Pipeline by Top 10 Indication, 2015
  • Vical Incorporated - Pipeline by Stage of Development, 2015
  • Vical Incorporated - Monotherapy Products in Pipeline, 2015
  • Vical Incorporated - Partnered Products in Pipeline, 2015
  • Vical Incorporated - Pipeline by Top 10 Target, 2015
  • Vical Incorporated - Pipeline by Top 10 Molecule Type, 2015
Back to Top